APP and Alzheimer disease: It has been reported that ginsenoside F1 was able to alter spatial memory deficits and inhibit or even reduce Aβ plaques in the cortex of APP/PS1 AD model mice, which may be related to its ability to increase the expression levels of pCREB and BDNF [138].